DCTHHealthcare · Medical DevicesThe 5 Wall Street analysts covering Delcath Systems, Inc. hold a median 12-month price target of $22 — +46.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 8 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Delcath Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (100): The business earns solid, repeatable profits on what it owns.
Growth (36): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DCTH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +46.3% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $30 → $32 |
| 6 Aug 2026 | BTIG | Maintains | Buy | $17 → $21 |
| 26 Feb 2026 | BTIG | Maintains | Buy | — |
| 26 Feb 2026 | BTIG | Maintains | Buy | $23 → $19 |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2025 | Stephens & Co. | Maintains | Overweight | — |
| 4 Nov 2025 | BTIG | Reiterates | Buy | — |
| 21 Oct 2025 | Canaccord Genuity | Maintains | Buy | — |
| 20 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 June 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 23 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Jan 2025 | Craig-Hallum | Maintains | Buy | — |
| 14 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Oct 2024 | Canaccord Genuity | Maintains | Buy | $21 |
| 18 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | $22 |
| 6 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Aug 2024 | Stephens & Co. | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DCTH appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Delcath Systems, Inc. returned +35.5% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 1% of US stocks
Cheaper than 22% of US stocks
Cheaper than 22% of US stocks
Cheaper than 98% of US stocks
Higher than 70% of US stocks
Higher than 35% of US stocks
Higher than 96% of US stocks
Higher than 61% of US stocks
Higher than 48% of US stocks
Higher than 45% of US stocks
Higher than 40% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Delcath Systems, Inc. has a market value of $534.7M and an enterprise value of $441.3M.
Revenue in the twelve months to 30 June 2026: $95.4M. The latest quarter grew 20.6% year on year.
Net income over the same four quarters: $532K, a 0.6% net margin.
Diluted earnings per share, trailing twelve months: $0.01.
Free cash flow in the twelve months to 30 June 2026: $17.5M.
Trailing P/E: 1541.0×; forward P/E: 342.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Delcath Systems, Inc. employs 156 people — $612K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Delcath Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The article compares the year-to-date performance of Delcath Systems (DCTH) and Encompass Health (EHC) against their sector.
Why it matters — A DCTH watcher would care because it shows how the company's stock has performed relative to its sector so far this year.
Delcath Systems announced that it granted Restricted Stock Units to four newly hired employees as material inducements under Nasdaq Listing Rule 5635(c)(4), with the grants totaling 34,000 RSUs. The equity awards were previously approved by the Company's Compensation Committee and relate to individuals whose employment commenced in July or August 2026.
Why it matters — This discloses new equity compensation tied to recent hires, which a Delcath watcher would consider relevant to share dilution and employee recruitment incentives.
Zacks screened VLO, PBF, FET and DCTH as low-beta picks as market volatility rises, citing growth drivers in refining, energy equipment and liver-cancer treatment for DCTH.
Why it matters — DCTH watchers would care because the article highlights the company as a lower-volatility option supported by its liver-cancer growth driver during periods of market turbulence.
Delcath Systems (DCTH) was named among five stocks showing strong recent price momentum after a strong August, with the strength backed by improving earnings expectations, according to Zacks Investment Research.
Why it matters — DCTH watchers would note that the stock's price strength is supported by improving earnings expectations, a positive fundamental signal for the company.
Delcath Systems announced that management will attend the Wells Fargo Healthcare Conference on September 10, 2026, in Boston, MA, and the H.C. Wainwright 27th Annual Global Investment Conference on September 15, 2026, in New York, NY. The company focuses on interventional oncology treatments for primary and metastatic cancers of the liver.
Why it matters — Participation in these investor conferences gives DCTH watchers an opportunity to hear management present the company's status and strategy to the investment community.
The 5 Wall Street analysts covering Delcath Systems, Inc. have a median 12-month price target of $22, with estimates ranging from $21 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Delcath Systems, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Delcath Systems, Inc. 96 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Delcath Systems, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (100 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +46.3% from the last close, and Ticker Nerd's factor model ranks Delcath Systems, Inc. 96 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Delcath Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCTH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $32 over the next 12 months.
Delcath Systems, Inc. returned +35.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
The most recent item we track (Zacks Investment Research, 15 Sept 2026): "Are Medical Stocks Lagging Delcath Systems (DCTH) This Year?". The article compares the year-to-date performance of Delcath Systems (DCTH) and Encompass Health (EHC) against their sector.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company develops and commercializes drug-device therapies designed to deliver high-dose chemotherapy directly to the liver while limiting systemic exposure and related side effects. Its current product portfolio includes HEPZATO KIT in the United States and CHEMOSAT in Europe, both used in hepatic delivery procedures for liver cancer care. Delcath Systems serves specialized oncology centers and medical professionals that treat patients with liver tumors, positioning its technologies within the broader medical device and specialty pharmaceutical markets. Headquartered in Queensbury, New York, Delcath Systems plays a focused role in targeted cancer treatment by combining pharmaceutical and device-based approaches for liver-directed therapy.
CEO Mr. Gerard J. Michel MBA, MS · 156 employees · United States · https://www.delcath.com
